Lv1
10 积分 2026-10-15 加入
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
2小时前
待确认
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
3小时前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
3小时前
已完结
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
3小时前
已完结
皖公网安备34019202002308
